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Summary.-The surface properties of blood lymphocytes from treated myeloma
patients and healthy controls were studied in vitro. The patients were tested 6 weeks
after the last treatment to allow time for cells to recover from possible drug toxicity.
Peripheral-blood lymphocytes were tested for rosette formation with unsensitized
sheep erythrocytes (E rosettes) and with complement and antibody-coated erythro-
cytes (EAC rosettes). The tests were duplicated using lymphocytes pretreated with
trypsin. As others have noted, myelomatosis is associated with increased blood levels
of EAC-rosette-forming cells and a marked reduction in E-rosette-forming cells.
E-rosetteformation was significantly increased bypretreatment ofmyelomalympho-
cytes with trypsin. By contrast, enzyme-treated cells showed no significant change
in EAC-rosette formation.
These results suggest that the absolute number of circulating T cells is probably
not reduced in myelomatosis, but that the surface of T cells is somehow modified so
that a proportion of them lose the ability to form E rosettes.
HUMAN T LYMPHOCYTES can be identi-
fied by their ability to form spontaneous
rosettes with unsensitized sheep red cells
(E rosettes) (Jondal et al., 1972; Minowada
et al., 1972) and by lack of surface-
membrane receptors for immunoglobulin
or complement components (C3b or C3d).
Human B lymphocytes can be identified
by their ability to form rosettes with
sensitized sheep erythrocytes (EAC
rosettes) (Bianco et al., 1970; Jondal et al.,
1972) and by the presence of receptors for
aggregated immunoglobulin.
Previous reports, from this laboratory
andfrom others, have shown that myeloma
patients have low levels of E-rosette-
forming lymphocytes, and a preponder-
ance of EAC-rosette-forming lymphocytes
(Mellstedt et al., 1973; Jones & McFarlane,
1975). However, it is not known whether
the subnormal levels of E-rosette-forming
cells were the consequence of a reduction
in the absolute number of circulating T
lymphocytes or of changes in the surface
properties ofthis population ofcells which
prevent them from forming E rosettes in
vitro.
It has recently been reported that pre-
treatment of normal peripheral blood
lymphocytes (PBL) with neuraminidase
significantly enhanced E- and EAC-
rosette formation (Galili & Schlesinger,
1974; Han & Minowada, 1976). The num-
ber of EAC rosettes slightly increased
when PBL from patients with chronic
lymphocyte leukaemia or acute lympho-
blastic leukaemia were pretreated with
Vibrio cholera neuraminidase (Han &
Minowada, 1976).
The present study was designed to in-
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vestigate the effect of trypsin treatment
on E- and EAC-rosette formation by
PBL from myeloma patients.
MATERIALS AND METHODS
Patients and controls.-The investigations
were carried out on 30 patients for whom the
diagnosis of myelomatosis had been well
established. This was based on the following
laboratory findings: (1) plasma-cell infiltra-
tion of marrow, as evidenced by the plasma
cells constituting more than 15% ofthe total
cell population of the aspirated marrow; (2)
presence of a monoclonal protein in the
serum and concentrated urine, as demon-
strated by cellulose acetate electrophoresis,
with a reduction in non-myeloma serum
immunoglobulins; and (3) in most cases the
presence of erosive changes in the skull,
vertebral column and pelvic bones as shown
on X-ray films. All the patients had received
several courses of the intermittent combina-
tion chemotherapeutic regime previously
described by Azam & Delamore (1974).
Healthy blood donors with normal lympho-
cyte counts (1000-4000/mm3) and receiving
no drugs, were studied as controls.
Collection of blood 8pecimens -Venous
blood specimens were collected in preserva-
tive-free heparin under sterile conditions. In
the case of myeloma patients, the following
protocol was adopted for blood collection.
Each course of treatment lasted 14 days
followed by a rest period of 6 weeks, thus
allowing sufficient time for marrow recovery
from the previous therapeutic course. Blood
samples were collected from the patients
before the next course oftreatment.
Lymphocyte preparation. -Lymphocytes
were separated from freshly collected venous
blood, under sterile conditions, by density-
gradient sedimentation in Ficoll-Triosil solu-
tion (Boyum, 1968). The cells were washed
x 3 and the pellet suspended in Dulbecco's
phosphate-buffered saline (PBS). Aliquots
from each lymphocyte suspension were
smeared and stained with Leishman stain.
The cell suspensions used in all experiments
were free ofred cells and composed of >95%
small lymphocytes. The viability of lympho-
cytes as revealed by the Trypan-blue dye
exclusion technique was >99% in all experi-
ments.
Enzyme.-A stock concentrated solution of
trypsin, 2.5% in calcium- and magnesium-
free PBS, was purchased from Flow Labora-
tories U.K. Its activity was checked with
N-benzoyl-L-arginine ethyl esterinphosphate
buffer (pH 7.6) as substrate.
Trypsinization of lymphocytes.-Separated
lymphocytes were resuspended in PBS at
105 cells/ml and each suspension was divided
into 2 or more equal fractions. After centri-
fugation the cell pellet was resuspended either
in trypsin solution (10-500 ,ug/ml trypsin in
PBS) or in PBS alone followed by incubation
at 37°C for 30-120 min without agitation.
The cell suspension was chilled on ice and
centrifuged at 4°C (300 g, 10 min) to sediment
the cells. The supernatants were removed, the
cell pellets were washed twice in PBS at 4°C
and finally resuspended in complete nutrient
medium composed of RPMI 1640 medium
supplemented with 10% foetal calf serum
(heat-inactivated) plus antibiotics. The re-
covery of lymphocytes after trypsinization
was determined by total cell counting, using
improved Neubauer's chambers, before and
after enzyme treatment, expressed as a
percentage.
In all experiments, the recovery was >97%
and the viability of both trypsin-treated and
untreated cells was usually >90%.
T-cell rosettes (E-binding lymphocytes).
0-25 ml of trypsinized and control lympho-
cyte suspensions containing 106 cells in
nutrient culture medium (RPMI 1640 supple-
mented with 10% heat-inactivated foetal calf
serum plus antibiotics) were allowed to form
spontaneous rosettes with 0-25 ml of a 1%
suspension of fresh, well washed sheep
erythrocytes (E) prepared in the same
medium. The mixture, contained in a wide
flat-bottomed 15 x41mm polyurethane tube,
was centrifuged at 200 g x2 min and in-
cubated at 40C for 16 h.
B-cell rosettes (EAC-binding lymphocytes).
5 ml of washed sheep erythrocytes were re-
suspended in nutrient medium to a concen-
tration of5% (v/v) and mixed with an equal
volume of rabbit antibody to sheep erythro-
cytes prediluted 1:2000 in culture medium
and incubated at 37°C for 30 min (MIellstedt
& Holm, 1973). After the incubation the cells
were washed x3 and resuspended in 5 ml of
culture medium. An equal volume of fresh
human serum diluted 1:20 with supple-
mented RPMI 1640 medium, as source of
complement, wasaddedandfurtherincubated
at room temperature for 30 min. The anti-
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body-complement-coated sheep erythrocytes
(EAC) were finally washed x3 and adjusted
to 1% (v/v) cell suspension in nutrient culture
medium. 0-25 ml ofthe EAC cells were mixed
with 0-25 ml of lymphocyte suspension
(trypsin-treated and untreated) in flat-
bottomed polyurethane tubes. After gentle
centrifugation (200 g, 5 min) and incubation
at ambient room temperature for 4 h, the
EAC rosettes were counted.
Before the rosettes were counted, most of
the supernatant was discarded from each tube
and the cells were gently tapped. Four
hundred cells were counted under a sealed
coverslip from each triplicate sample and
lymphocytes binding more than 3 E or EAC
erythrocytes were regarded as rosette-form-
ing. The final result ofeach rosetting cell type
was expressed as a percentage of absolute
total cell population, modified from the
method described by Dellom (1974).
RESULTS
Optimum trypsin concentration
The effect of exposing lymphocytes to
varying concentrations of trypsin on the
percentage of E-binding lymphocytes is
shown in Fig. 1. The most striking finding
was that the proportion of myeloma
lymphocytes forming E rosettes increased
with increasing trypsin concentration and
reached the maximum level when the
trypsin concentration was 300 ,ug/ml.
Greater concentrations of trypsin (up to
500 /g/ml) reduced the mean percentage
of E-rosette-forming cells. However, the
mean percentage of trypsinized myeloma
lymphocytes forming E rosettes remained
significantly higher (P< 0 01) than the
percentage for untrypsinized myeloma
lymphocytes. By contrast, exposure of
normal lymphocytes to trypsin caused a
marked reduction in the mean percentage
of E-rosette-forming cells. At 300 ,ug/ml
trypsin, the percentage of E-rosette-
forming cells was reduced to about 80%
of that for untrypsinized normal lympho-
cytes. This was further reduced to 60%
when the trypsin concentration was in-
creased to 500 ,tg/ml. However, the mean
percentage of trypsinized myeloma
lymphocytes forming E rosettes was sig-
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FIG. 1. Changes in E rosette (T cells) when
peripheral-blood lymphocytes (PBL) were
treated with different concentrations of
trypsin. Ficoll-Triosil-gradient purified
lymphocytes at a concentration of 105
cells/ml of trypsin solution (10-500 t,g//ml
in PBS) were incubated at 37°C for 90 min.
About 106 cellwereused forE rosetteforma-
tion in each incubation as detailed in the
Methods section. The data presented are
mean (± s.d.) of duplicate incubations of
individual samples from 5myelomapatients
receiving treatment (0 O) and 5 nor-
mal blood donors (--- -0). Note that at
300 pg/ml trypsin concentration there was
significant (P<0.001) increase in E roset-
ting in myeloma patients' lymphocyte
population. In contrast, there was pro-
gressive decrease in E rosettes formed by
normal donors' lymphocytes as trypsin
concentration increased (P < 0.01).
50
500
nificantly lower than that of trypsinized
normal lymphocytes (P< 0 02).
Optimum incubation time
The mean percentage of E-rosette-
forming lymphocytes from myeloma
patients and normal donor PBL before
and after exposure to 300 ,ug/ml trypsin
for varying incubation times at 37°C is
presented in Fig. 2. The percentage of E-
rosette-forming cells within the population
of trypsinized myeloma lymphocytes in-
creased steadilywithtime, reaching a peak
at 90 min incubation. The mean percent-
age of untrypsinized myeloma cells form-
ing E rosettes remained relatively con-
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FIG. 2. Correlation between duration oftryp-
sinization and the percentage of E rosettes
formed. 3Q0 ,tg trypsin/ml was used
throughout. (A A) =trypsin-treated
myeloma lymphocytes, (0 *) = un-
treated myeloma lymphocytes, (0 0)
=trypsin-treated normal donor lympho-
cytes, and (0 O) =untreated normal
donor lymphocytes. Note that at 90 min
there was maximum effect oftrypsin on the
myeloma PBL andthat there was aninverse
relationship between the trypsin-treated
myeloma and trypsin-treated normal lym-
phocytes. After trypsinization of the my-
eloma cells, their ability to form E
rosettes approached that of untrypsinized
normal lymphocytes.
stant at all incubation times. By contrast,
the trypsinized normal lymphocytes
showed a dramatic fall in the mean per-
centage of E-rosette-forming lymphocytes
with increasing incubation time. Normal
lymphocytes exposed to trypsin showed a
slightly lower capacity to form spon-
taneous rosettes with sheep erythrocytes
after incubation at 37TC for 90 min. How-
MYELOMA NORMAL DONOR
LYMPHOCYTES LYMPHOCYTES
FIG. 3. Comparative effect oftrypsinization
on spontaneous rosette formation with
sheeperythrocytes (SRBC) the markerforE
receptors onhumanPBL (Tcell) membrane.
The mean for 30 individual patients and
donors is indicatedbythebar. Theoptimum
conditions of trypsinization were used.
Solid symbols, trypsinized. Open symbols,
untrypsinized.
ever, after 90min incubation, the effect of
trypsin on the myeloma PBL was maxi-
mal, and an inverse relationship existed
between the trypsin-treated myeloma and
trypsin-treated normal lymphocytes.
Exposure to trypsin: effect on E rosettes
(T cells)
Having established optimal conditions
of trypsin treatment for differentiating
myeloma patients and blood donors in a
limited number of cases, the effect of
trypsinization on E rosettes of PBL from
a larger group of myeloma patients and
normal blood donors was studied (Fig. 3
TABLE.-Statistical analysis; Effects of trypsinization on E and EAC rosettes formed by
lymphocytesfrom myeloma patients and normal donors
E rosette
-n
A B
55-4+13-la 34-0+12-4b
17-1 + 11-8c 26-8+12-8d
EAC rosette
A B
39-6 + 9-3e 36-1 +8-Of
56-0+12-9g 53-5+11-Oh
Results are mean + s.d. A = untreated and B = trypsin-treated peripheral-blood lymphocytes. Statistically analysed for significance by Student's t test on paired samples and Wilcoxon matched signed rank test.
avsb=P<0.001;cvsd=P<0.001;evsf=P>0-05;gvsh=P>0-05;avsc=P<0001;bvsd=P<0-020; evsg=P<0-001;fvsh=P<0-001.
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FiG. 4. Comparative effect of trypsinization
on rosette formation with antibody-
complement-coated sheep erythrocytes
(EAC). Fresh human serum was used as the
source of complement and rabbit antisera
to sheep erythrocytes were used as anti-
body. Optimum conditions of lymphocyte
trypsinization were used. The data rep-
resent the mean ( ) and individual results
from 30 individual myeloma patients and 30
healthy controls. Open symbols untreated.
Solid symbols, trypsinized. Note the higher
number of EAC rosettes of both trypsin-
treated and untreated myeloma lympho-
cytes compared to that of normal lympho-
cytes. However, after trypsinization there
was a reduction of EAC rosettes formed by
both the normal and myeloma lympho-
cytes.
and the Table). The E rosette was sig-
nificantly increased when PBL ofmyeloma
patients were pretreated with trypsin
(P < 0-001). In contrast, PBL from normal
donors after trypsinization showed a sig-
nificantly marked reduction of E rosettes
(P < 0001) and untrypsinized myeloma
lymphocytes had a significantly lower E-
rosette level than untrypsinized normal
lymphocytes (P < 0 001). Similarly, the
trypsinized myeloma lymphocytes showed
a significantly lower E-rosette level than
trypsin-treated normal donor lympho-
cytes (P < 0-02).
Exposure to trypsin: effect on EAC rosettes
(B cells)
The comparative effect oftrypsinization
on rosette formation with sensitized sheep
erythrocyte by normal and malignant
P13L is presented in Fig. 4 and the Table.
A slight reduction of EAC rosettes was
seen when the PBL from myeloma
patients or normal donors were pretreated
with trypsin. The reduction was, however,
not statistically significant. The EAC-
rosette level of trypsinized and untryp-
sinized myeloma lymphocytes was sig-
nificantly higher than that of trypsinized
and untreated normal lymphocytes re-
spectively (P< 0.001).
DISCUSSION
This investigation provides evidence
that trypsinization of lymphocytes from
treated myeloma patients increased the
proportion able to form spontaneous
rosettes with sheep erythrocytes. Under
the same conditions trypsin depressed the
numbers of lymphocytes from normal
donors able to form E rosettes. An in-
teresting aspect of the result is that the
proportion of E-binding cells from the
trypsin-treated myeloma lymphocyte
population slightly but consistently ex-
ceeded that of normal lymphocytes pre-
treated with trypsin at concentrations
above 200 Htg/ml (Fig. 1).
The depressed E-rosette formation by
trypsin-treated normal lymphocytes con-
firmed the suggestion that the sheep
erythrocyte receptor sites on the lympho-
cyte surface membrane are sensitive to
trypsin and may be protein in nature
(Wybran et al., 1972). An alternative
explanation is that the surface changes on
normal lymphocyte membranes have been
markedly altered by trypsin, so that the
electrostatic attraction between the
lymphocyte and sheep erythrocyte had
been reduced.
Although the exact mechanism of
trypsin-induced enhancement of myeloma
lymphocyte capacity to form spontaneous
rosettes with sheep erythrocytes is not
clearly understood, it is most likely to be
related to changes in the surface-mem-
brane properties of the cells following
trypsinization. Acute-phase proteins (e.g.
C-reactive protein) which are considerably
increased in malignancy, suppress several
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functions of T lymphocytes (Mortensen
et al., 1975). It is conceivable that the
receptor sites on the surface membrane of
malignant lymphoid cells were masked by
serum factors which may be elaborated by
the cells or absorbed on to the cell surface,
and that trypsinization relieves this in-
hibition. Identification of the surface-
membrane trypsinates from myeloma
lymphocytes by double immunodiffusion
showed the presence ofC-reactive protein,
oxi-antitrypsin and 012-macroglobulin (un-
published data).
Augmentation of E-rosette formation
by lymphocytes from myeloma patients
following trypsinization suggests that T
lymphocytes were present, and that their
responsiveness can be partially or com-
pletely restored. Furthermore, the E-
rosette formation which has been widely
used as a means of determining the total
T-cell population in patients with various
types of malignant diseases (Mellstedt et
al., 1973; Nemoto et al., 1974; Jones &
McFarlane, 1975) may in certain circum-
stances provide inaccurate estimates of
the absolute number of circulating T
lymphocytes. In these cases the technique
should be extended by the use ofenzymes.
The effect of acute-phase proteins on
surface-membrane-associated functions
and properties of normal lymphocytes is
currently being investigated.
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